MedPath

Study of the Spermatic Characteristics of Patients With Fabry Disease

Not Applicable
Completed
Conditions
Fabry Disease
Interventions
Procedure: Semen collection
Registration Number
NCT04073888
Lead Sponsor
University Hospital, Bordeaux
Brief Summary

The objective of this project is to estimate the prevalence of spermatic abnormalities in patients with Fabry disease.The main objective of this project is to estimate the prevalence of spermatic abnormalities in patients with Fabry disease.

Detailed Description

Fabry disease is a lysosomal storage burden of X-linked genetic transmission due to alpha-galactosidase deficiency. This enzyme deficiency causes deposits of globotriaosylceramide in virtually all cell types of the body. The majority of hemizygous men develop a severe multisystemic disease dominated by renal failure, neurological and cardiac involvement. There is a specific treatment based on enzyme replacement therapy.

The incidence of Fabry disease is estimated between 1/60000 and 1/3500 in the general population.

Infertility in Fabry disease is poorly documented. Only a few cases have been reported, from alteration of spermogram to azoospermia. The identification of deposits suggestive of Gb3 in light microscopy and electron microscopy at the level of the genital tract argues in favor of the attack of this device. The low prevalence of Fabry disease requires a cross-sectional multicenter study to determine the frequency of alterations in sperm characteristics, their impact on fertility, and the possible effect of substitution therapy, in order to establish appropriate measures. adequate preventive measures.

The objective of this project is to estimate the prevalence of spermatic abnormalities in patients with Fabry disease.The main objective of this project is to estimate the prevalence of spermatic abnormalities in patients with Fabry disease.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
22
Inclusion Criteria
  • male patients with Fabry disease regardless of the clinical form of the disease; treated with enzyme replacement therapy or not (from the initial diagnosis). The definite diagnosis of Fabry disease will be established on the deficit of the activity of alpha galactosidase A (<12%). A molecular genetic study is desirable but not mandatory,
  • patients aged 18 to 65,
  • giving their free and informed consent to participate, after information on the research.
Exclusion Criteria
  • persons placed under the protection of justice,
  • unaffiliated or non-beneficiary subject of a social security scheme.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Single armSemen collectionMen with Fabry Disease
Primary Outcome Measures
NameTimeMethod
Existence of leukospermia yes/noAt Day 1

Spermogram characteristics

% of typical forms of spermatozoidsAt Day 1

Characteristics of spermocytogram

volume (ml) of spermAt Day 1

Spermogram characteristics

pH of spermAt Day 1

Spermogram characteristics

Multiple Anomalies Index (MAI) of spermatozoidsAt Day 1

Characteristics of spermocytogram

Total number of progressive motile spermatozoaAt Day 1

Spermogram characteristics

Count (million / ml) of spermatozoidsAt Day 1

Spermogram characteristics

Mobility (%) and mobility type of spermatozoa according to WHO classification of spermatozoidsAt Day 1

Spermogram characteristics

Total number of spermatozoa in one ejaculateAt Day 1

Spermogram characteristics

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath